Treatment of HIV infection with raltegravir

被引：0
|
作者：
Chirch, Lisa M. [1 ]
Morrison, Sidonie A. [1 ]
Steigbigel, Roy T. [1 ]
机构：
[1] SUNY Stony Brook, Sch Med, Div Infect Dis, Stony Brook, NY 11794 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2009年 / 10卷 / 07期
关键词：
antiretroviral therapy; HIV; human immunodeficiency virus; integrase inhibitor; raltegravir; INTEGRASE INHIBITOR RALTEGRAVIR; STRAND TRANSFER; PHARMACOKINETICS; TOLERABILITY; MK-0518; THERAPY; SAFETY; VIRUS;
D O I：
10.1517/14656560902911488
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus. Objective: To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability. Methods: Data from pharmacokinetic, Phase II and III clinical trials were reviewed. Results/conclusions: Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naive and -experienced patients.
引用
收藏
页码：1203 / 1211
页数：9
相关论文
共 50 条
  • [31] Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity
    Funderburg, Nicholas T.
    Xu, Dihua
    Playford, Martin P.
    Joshi, Aditya A.
    Andrade, Adriana
    Kuritzkes, Daniel R.
    Lederman, Michael M.
    Mehta, Nehal N.
    ANTIVIRAL THERAPY, 2017, 22 (01) : 71 - 75
  • [32] Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy
    Dahl, Viktor
    Lee, Evelyn
    Peterson, Julia
    Spudich, Serena S.
    Leppla, Idris
    Sinclair, Elizabeth
    Fuchs, Dietmar
    Palmer, Sarah
    Price, Richard W.
    JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (12): : 1936 - 1945
  • [33] Combination Antiretroviral Therapy With Raltegravir Leads to Rapid Immunologic Reconstitution in Treatment-Naive Patients With Chronic HIV Infection
    Pallikkuth, Suresh
    Fischl, Margaret A.
    Pahwa, Savita
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (10): : 1613 - 1623
  • [34] 抗HIV新药raltegravir
    谭艳梅
    刘川
    赵桂森
    中国新药杂志, 2007, (21) : 1812 - 1815
  • [35] RALTEGRAVIR IS THE FIRST HIV INTEGRASE INHIBITOR AS PART OF ANTIRETROVIRAL TREATMENT REGIMENS
    Kravchenko, A. V.
    TERAPEVTICHESKII ARKHIV, 2010, 82 (11) : 27 - 32
  • [36] Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir (vol 25, pg 2069, 2011)
    Kersten, K. K.
    Christoph, B.
    Kristin, M.
    Linda, G.
    Paul, F.
    Ven, N.
    AIDS, 2012, 26 (11) : 1455 - 1455
  • [37] Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir (vol 25, pg 2069, 2011)
    Koelsch, K. K.
    Seddiki, Nabila
    AIDS, 2012, 26 (18) : 2425 - 2425
  • [38] RaltegravirVirological failure secondary to raltegravir resistance to HIV-1 infection: case report
    Reactions Weekly, 2017, 1670 (1) : 240 - 240
  • [39] Darunavir/efavirenz/raltegravirEmergence of raltegravir resistance in HIV-1 infection: case report
    Reactions Weekly, 2011, 1363 (1) : 16 - 16
  • [40] Raltegravir: A Review of Its Use in the Management of HIV-1 Infection in Children and Adolescents
    Perry, Caroline M.
    PEDIATRIC DRUGS, 2014, 16 (01) : 91 - 100
12345